Structural organization of C60 fullerene, doxorubicin, and their complex in physiological solution as promising antitumor agents
Source abstract
Abstract
Specific features of structural self-organization of C60 fullerene (1 nm size range), antitumor antibiotic doxorubicin (Dox) and their complex in physiological solution (0.9 % NaCl) have been investigated by means of atomic-force microscopy, dynamic light scattering, and small-angle X-ray scattering. Significant ordering of the mixed system, C60 + Dox, was observed, suggesting the complexation between these drugs, and giving insight into the mechanism of enhancement of Dox antitumor effect on simultaneous administration with C60 fullerene.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Fullerene Chemistry and Applications · Graphene research and applications · Boron and Carbon Nanomaterials Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Amer MS, Elliott JA, Maguire JF, Windle AH (2005) Calculations of the Raman spectra of C60 interacting with water molecules. Chem Phys Lett 411:395–39810.1016/j.cplett.2005.06.057 ↗
2. Andrievsky GV, Klochkov VK, Bordyuh AB, Dovbeshko GI (2002) Comparative analysis of two aqueous-colloidal solutions of C60 fullerene with help of FTIR reflectance and UV-Vis spectroscopy. Chem Phys Lett 364:8–1710.1016/S0009-2614(02)01305-2 ↗
3. Aschberger K, Johnston HJ, Stone V, Aitken RJ, Tran CL, Hankin SM et al (2010) Review of fullerene toxicity and exposure-appraisal of a human health risk assessment, based on open literature. Regul Toxicol Pharmacol 58:455–47310.1016/j.yrtph.2010.08.017 ↗
4. Avdeev MV, Khokhryakov AA, Tropin TV, Andrievsky GV, Klochkov VK, Derevyanchenko LI et al (2004) Structural features of molecular-colloidal solutions of C60 fullerenes in water by small-angle neutron scattering. Langmuir 20:4363–436810.1021/la0361969 ↗
5. Balch AL, Olmstead MM (1999) Structural chemistry of supramolecular assemblies that place flat molecular surfaces around the curved exteriors of fullerenes. Coord Chem Rev 185–186:601–61710.1016/S0010-8545(99)00013-2 ↗
6. Boyd PDW, Reed CA (2005) Fullerene-porphyrine constructs. Acc Chem Res 38:235–24210.1021/ar040168f ↗
7. Brant J, Lecoanet H, Wiesner MR (2005) Aggregation and deposition characteristics of fullerene nanoparticles in aqueous systems. J Nanopart Res 7:545–55310.1007/s11051-005-4884-8 ↗
8. Buchelnikov AS, Evstigneev MP (2014) Quantitative correlation of the in vitro biological effect with parameters of molecular complexation in mutagen-interceptor systems. J Theor Biol 357:268–27110.1016/j.jtbi.2014.06.016 ↗
9. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ (2014) Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34:106–13510.1002/med.21280 ↗
10. Cataldo F, Da Ros T (eds) (2008) Medicinal chemistry and pharmacological potential of fullerenes and carbon nanotubes. Carbon materials: chemistry and physics, vol 1. Springer, Dordrecht10.1007/978-1-4020-6845-4 ↗
11. Chen KL, Elimelech M (2009) Relating colloidal stability of fullerene (C60) nanoparticles to nanoparticle charge and electrokinetic properties. Environ Sci Technol 43:7270–727610.1021/es900185p ↗
12. Dallavalle M, Leonzio M, Calvaresi M, Zerbetto F (2014) Explaining fullerene dispersion by using micellar solutions. ChemPhysChem 15:2998–300510.1002/cphc.201402282 ↗
13. Deguchi S, Alargova RG, Tsujii K (2001) Stable dispersions of fullerenes, C60 and C70, in water. Preparation and characterization. Langmuir 17:6013–601710.1021/la010651o ↗
14. Evstigneev MP (2014) Hetero-association of aromatic molecules in aqueous solution. Int Rev Phys Chem 33:229–27310.1080/0144235X.2014.926151 ↗
15. Evstigneev MP, Buchelnikov AS, Voronin DP, Rubin YuV, Belous LF, Prylutskyy YuI et al (2013) Complexation of C60 fullerene with aromatic drugs. ChemPhysChem 14:568–57810.1002/cphc.201200938 ↗
16. Fortner JD, Lyon DY, Sayes CM, Boyd AM, Falkner JC, Hotze EM et al (2005) C60 in water: nanocrystal formation and microbial response. Environ Sci Technol 39:4307–431610.1021/es048099n ↗
17. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F (2005) [C60] fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 5:2578–258510.1021/nl051866b ↗
18. Hirsch A, Brettreich M, Wudl F (2005) Fullerenes: chemistry and reactions. Wiley, New York
19. Labille J, Masion A, Ziarelly F, Rose J, Brant J, Villieras F et al (2009) Hydration and dispersion of C60 in aqueous systems: the nature of water-fullerene interactions. Langmuir 25:11232–1123510.1021/la9022807 ↗
20. Montellano A, Da Ros T, Bianco A, Prato M (2011) Fullerene C60 as multifunctional system for drug and gene delivery. Nanoscale 3:4035–404110.1039/c1nr10783f ↗
21. Panchuk RR, Prylutska SV, Chumak VV, Skorokhyd NR, Lehka LV, Evstigneev MP et al (2015) Application of C60 fullerene-doxorubicin complex for tumor cell treatment in vitro and in vivo. J Biomed Nanotechnol 11:1139–115210.1166/jbn.2015.2058 ↗
22. Piosik J, Zdunek M, Kapuscinski J (2002) The modulation by xanthines of the DNA-damaging effect of polycyclic aromatic agents, part II. The stacking complexes of caffeine with doxorubicin and mitoxantrone. Biochem Pharmacol 63:635–64610.1016/S0006-2952(01)00903-0 ↗
23. Prylutska SV, Grynyuk II, Matyshevska OP, Prylutskyy YuI, Ritter U, Scharff P (2008) Anti-oxidant properties of C60 fullerenes in vitro. Fuller Nanotub Carbon Nanostruct 16:698–70510.1080/15363830802317148 ↗
24. Prylutska SV, Burlaka AP, Klymenko PP, Grynyuk II, Prylutskyy YuI, Schuetze Ch et al (2011) Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnol 2:105–11010.1007/s12645-011-0020-x ↗
25. Prylutska S, Bilyy R, Overchuk M, Bychko A, Andreichenko K, Stoika R et al (2012) Water-soluble pristine fullerenes C60 increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. J Biomed Nanotechnol 8:522–52710.1166/jbn.2012.1404 ↗
26. Prylutska S, Grynyuk I, Matyshevska O, Prylutskyy Y, Evstigneev M, Scharff P, Ritter U (2014) C60 fullerene as synergistic agent in tumor-inhibitory doxorubicin treatment. Drugs R D 14:333–34010.1007/s40268-014-0074-4 ↗
27. Prylutskyy YuI, Buchelnikov AS, Voronin DP, Kostjukov VV, Ritter U, Parkinson JA et al (2013) C60 fullerene aggregation in aqueous solution. Phys Chem Chem Phys 15:9351–936010.1039/c3cp50187f ↗
28. Prylutskyy YuI, Petrenko VI, Ivankov OI, Kyzyma OA, Bulavin LA, Litsis OO et al (2014a) On the origin of C60 fullerene solubility in aqueous solution. Langmuir 30:3967–397010.1021/la404976k ↗
29. Prylutskyy YuI, Evstigneev MP, Pashkova IS, Wyrzykowski D, Woziwodzka A, Gołuński G et al (2014b) Characterization of C60 fullerene complexation with antibiotic doxorubicin. Phys Chem Chem Phys 16:23164–2317210.1039/C4CP03367A ↗
30. Skamrova GB, Laponogov I, Buchelnikov AS, Shckorbatov YG, Prylutska SV, Ritter U et al (2014) Interceptor effect of C60 fullerene on the in vitro action of aromatic drug molecules. Eur Biophys J 43:265–27610.1007/s00249-014-0960-2 ↗
31. Traganos F, Kapuscinski J, Darzynkiewicz Z (1991) Caffeine modulates the effects of DNA-intercalating drugs in vitro: a flow cytometric and spectrophotometric analysis of caffeine interaction with novantrone, doxorubicin, ellipticine, and the doxorubicin analogue AD198. Cancer Res 51:3682–3689
32. Woziwodzka A, Gołuński G, Wyrzykowski D, Kaźmierkiewicz R, Piosik J (2013) Caffeine and other methylxanthines as interceptors of food-borne aromatic mutagens: inhibition of Trp-P-1 and Trp-P-2 mutagenic activity. Chem Res Toxicol 26:1660–167310.1021/tx4002513 ↗